前沿速览059期| CAR-T治B淋 前沿览新知
01
CXCR4修饰可通过改善肿瘤追踪与骨髓归巢能力提升CAR-T细胞在B细胞恶性肿瘤中的疗效
CXCR4-modification enhances CAR-T efficacy by improving tumor tracking and bone marrow homing in B-cell malignancies
第一作者：Shu P
Signal Transduct Target Ther (IF=52.7). 2026 Jan 28;11(1):38.
全文网址：https://pmc.ncbi.nlm.nih.gov/articles/PMC12852854/
02
CD19 CAR-T细胞治疗腿型原发性皮肤弥漫大B细胞淋巴瘤
CD19 CAR T-cell therapy in primary cutaneous diffuse large B-cell lymphoma, leg type
第一作者：Escribano-Serrat S
Am J Hematol (IF=10.3). 2026 Jan 30.
全文网址：https://onlinelibrary.wiley.com/doi/10.1002/ajh.70218
03
CAR-T对比历史治疗方案可改善复发/难治性大B细胞淋巴瘤患者的生存结局与医疗资源利用
Improved survival and healthcare utilization with CAR-T vs historical care in relapsed-refractory large B-cell lymphoma
第一作者：Kordbacheh T
Blood Adv (IF=7.1). 2026 Jan 16:bloodadvances.2025017401.
全文网址：https://ashpublications.org/bloodadvances/article-lookup/doi/10.1182/bloodadvances.2025017401?__cf_chl_rt_tk=b9k37Tifh9MRmI8XhtOVku_P.Y5ysnZNVhA1pRpg05I-1769999222-1.0.1.1-2ASjDE4L8OKV16Rktas_q.0MB0gJxWE.qjxD8GNPLNc
04
Brexucabtagene autoleucel治疗复发/难治性套细胞淋巴瘤：德国与瑞士常规临床实践中的结局分析
Results of brexucabtagene-autoleucel for patients with relapsed/refractory mantle cell lymphoma in the routine setting in germany and switzerland
第一作者：Simon L
Bone Marrow Transplant (IF=5.2). 2026 Jan 16.
全文网址：https://www.nature.com/articles/s41409-025-02789-7
05
单采CD8(+)CCR7(+)CD45RA(-) T细胞可作为预测CAR-T细胞动力学特征与临床预后的新型生物标志物
Apheresis CD8(+)CCR7(+)CD45RA(-) T-Cells as a novel biomarker associated with CAR T-cell kinetics and clinical outcome
第一作者：García de la Torre I
Int J Mol Sci (IF=4.9). 2026 Jan 15;27(2):866.
全文网址：https://pmc.ncbi.nlm.nih.gov/articles/PMC12841578/
06
独特的环状结构双特异性CD19/CD22 CAR-T细胞治疗复发/难治性弥漫大B细胞淋巴瘤：一项观察性临床研究
Unique loop-structured CD19/CD22 bispecific CAR-T-cell therapy for patients with relapsed/refractory diffuse large B-cell lymphoma: an observational study
第一作者：Li S
Antib Ther (IF=4.5). 2025 Nov 20;9(1):24-37.
全文网址：https://pmc.ncbi.nlm.nih.gov/articles/PMC12804173/
07
CAR-T细胞治疗大B细胞淋巴瘤的长期临床结局与晚期毒性分析
Long-term outcomes and late toxicities of CAR T-cell therapy in large B-cell lymphoma
第一作者：Litvin R
Expert Opin Biol Ther (IF=4.0). 2026 Jan 27.
全文网址：https://www.tandfonline.com/doi/10.1080/14712598.2026.2621889?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
08
Tisagenlecleucel治疗复发或难治性大B细胞淋巴瘤的真实世界临床结局：一项全国性登记研究
Real-world outcomes of tisagenlecleucel treatment in patients with relapsed or refractory large B-cell lymphomas: a nationwide registry
第一作者：Sakurai M
Cytotherapy (IF=3.2). 2025 Dec 24;28(3):102042.
全文网址：https://www.isct-cytotherapy.org/article/S1465-3249(25)00938-7/abstract
09
优化CAR-T细胞单采采集效率的实用预测指标构建研究
Establishing practical predictors of collection efficiency for optimized chimeric antigen receptor T-cell apheresis
第一作者：Kim HJ
Cytotherapy (IF=3.2). 2025 Dec 24;28(3):102038.
全文网址：https://www.isct-cytotherapy.org/article/S1465-3249(25)00934-X/abstract
10
CAR-T细胞治疗伴TP53突变的中枢神经系统淋巴瘤：可突破高危遗传学障碍
CAR-T cell therapy in TP53-mutated CNS lymphoma: overcoming a high-risk genetic barrier
第一作者：Li D
Front Med (Lausanne) (IF=3.0). 2026 Jan 13;12:1731589.
全文网址：https://pmc.ncbi.nlm.nih.gov/articles/PMC12835395/
免责声明：本资料为专业医学资料，旨在促进医药信息的沟通和交流，仅供医疗卫生专业人士参考；任何处方请参考产品最新详细处方资料。本文件可能包含涉及医学情况、健康及治疗方法的信息。相关信息不得用作诊断或治疗，不能替代专业医学意见。
审批编号：NP-NHL-2026.2-2 valid until 2028.2
供稿与审核：临床开发与医学部